Department of Clinical Biology, Hôpital Foch, Suresnes, France.
Department of Clinical Biology, Hôpital Foch, Suresnes, France.
Diagn Microbiol Infect Dis. 2021 Jul;100(3):115368. doi: 10.1016/j.diagmicrobio.2021.115368. Epub 2021 Mar 12.
Temocillin is used for several years in some European countries but, only since 2015 in France. We assessed the susceptibility of Enterobacterales strains isolated from blood culture 1 year before (2014) and 2 years after (2017) its use in France. 1,387 strains were included by 17 clinical laboratories located throughout France: 363 in 2014 and 1,024 in 2017. The rate of resistance to temocillin was 4.6% and 26.7% in 3rd generation cephalosporin (3GC) susceptible and resistant strains respectively. Cephalosporinase-overproducer (COPE) strains were significantly more resistant to temocillin (37.7%) than ESBL-producer (ESBL-PE) (23.5%) (P < 0.01). The rate of temocillin resistance was correlated to the number of inactive beta-lactams. The rate of resistance to temocillin trend to increase from 13.9% in 2014 to 23.9% in 2017 (P < 0.01). Temocillin remains highly active against Enterobacterales but the trend in resistance should be assessed over time.
替莫西林在一些欧洲国家已经使用了多年，但直到 2015 年才在法国使用。我们评估了替莫西林在法国使用前一年（2014 年）和使用后两年（2017 年）从血培养中分离的肠杆菌科菌株的敏感性。17 家临床实验室在法国各地共纳入了 1387 株菌株：2014 年 363 株，2017 年 1024 株。在第三代头孢菌素（3GC）敏感和耐药菌株中，替莫西林的耐药率分别为 4.6%和 26.7%。产头孢菌素酶（COPE）菌株对替莫西林的耐药率（37.7%）明显高于产超广谱β-内酰胺酶（ESBL-PE）菌株（23.5%）（P < 0.01）。替莫西林的耐药率与失活β-内酰胺的数量相关。2014 年至 2017 年，替莫西林耐药率从 13.9%上升至 23.9%（P < 0.01）。替莫西林对肠杆菌科仍具有高度活性，但耐药趋势应随时间进行评估。
